Search - tctmd.com

Displaying 161 - 180 of 415

Sort: Relevancy | Date

News Opinion CV Team Dispatch

February 2023 News Roundup

L.A. McKeown

February 15, 2023

News Daily News

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

L.A. McKeown

January 24, 2023

News Daily News

RECORD4 Trial of Rivaroxaban, Published in 2009, Still Turning Heads

Todd Neale

January 19, 2023

News Daily News

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

Michael O'Riordan

January 16, 2023

News Daily News

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

L.A. McKeown

January 13, 2023

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

News Daily News

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Michael O'Riordan

December 30, 2022

News Daily News

Anatomic Disease After PCI Linked With Worse Outcomes: VA CART

Michael O'Riordan

December 22, 2022

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Daily News

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Michael O'Riordan

November 17, 2022

News Daily News

Novel Aldosterone Synthase Inhibitor Drops BP: Top-line Phase II Results

Todd Neale

November 16, 2022

News Conference News AHA 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Michael O'Riordan

November 07, 2022

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

News Opinion CV Team Dispatch

November 2022 News Roundup

L.A. McKeown

November 01, 2022

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

L.A. McKeown

October 05, 2022

GDMT With ARNI Lessens MR, Perhaps Obviating Need for Interventions

News Conference News HFSA 2022

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Michael O'Riordan

October 04, 2022

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

News Daily News

New on the Scene Nonstatin Drugs: Experts Provide Guidance

Caitlin E. Cox

August 31, 2022

Advertisement

February 2023 News Roundup

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

RECORD4 Trial of Rivaroxaban, Published in 2009, Still Turning Heads

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Anatomic Disease After PCI Linked With Worse Outcomes: VA CART

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Novel Aldosterone Synthase Inhibitor Drops BP: Top-line Phase II Results

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

November 2022 News Roundup

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

CV Care Around Noncardiac Surgery: New ESC Guidelines

New on the Scene Nonstatin Drugs: Experts Provide Guidance

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content